Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Survival Outcomes in the Canadian Merkel Cell Carcinoma Population Between 2000 and 2018 and Descriptive Comparison with the American Joint Committee on Cancer 8th Edition Staging System-A Study from the Pan-Canadian Merkel Cell Collaborative.

Cancers·2025

Same author

Role of a Polyphenol-Enriched Blueberry Preparation on Inhibition of Melanoma Cancer Stem Cells and Modulation of MicroRNAs.

Biomedicines·2024

Same author

Skin Investigation Network of Canada (SkIN Canada) Priority Setting Initiative ranks the top 10 evidence uncertainties for Merkel cell carcinoma.

The British journal of dermatology·2023

Same author

Prioritizing Melanoma Surgeries to Prevent Wait Time Delays and Upstaging of Melanoma during the COVID-19 Pandemic.

Current oncology (Toronto, Ont.)·2023

Same author

Data Dissemination of the Role of Neoadjuvant Radiation in Retroperitoneal Sarcoma: A CTOS and CSSO Survey.

Current oncology (Toronto, Ont.)·2023

Same author

Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma.

Current oncology (Toronto, Ont.)·2023

Search research articles

Related Experiment Video

Updated: Sep 30, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Retroperitoneal Sarcoma Care in 2021.

Erika Schmitz^1,2, Carolyn Nessim^1,2,3

¹Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

|March 10, 2022

Summary

Retroperitoneal sarcomas are rare cancers. Current standard treatment involves surgery, but radiation and systemic therapies like immunotherapy lack established protocols, necessitating further research and clinical trials.

Keywords:

radiation therapy retroperitoneal sarcoma sarcoma soft-tissue tumor systemic therapy

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

Related Experiment Videos

Last Updated: Sep 30, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

Area of Science:

Oncology
Surgical Oncology

Background:

Retroperitoneal sarcomas are rare, aggressive cancers originating from connective tissues, comprising less than 10% of all sarcomas.
Despite advancements, treatment for these tumors remains challenging due to their complex anatomy and biological heterogeneity.

Purpose of the Study:

To review the anatomical boundaries, clinical characteristics, and current treatment standards for retroperitoneal sarcomas.
To highlight recent advancements and areas of ongoing research in managing this rare malignancy.

Main Methods:

Comprehensive literature review of retroperitoneal sarcoma management.
Analysis of contemporary treatment strategies, including surgery, radiation, and systemic therapies.
Discussion of evidence-based guidelines and expert consensus.

Main Results:

Upfront primary surgical resection is the current standard of care for retroperitoneal sarcomas.
The role of adjuvant radiation therapy remains controversial, with no definitive consensus.
Systemic therapy, including immunotherapy, lacks a standardized treatment protocol.

Conclusions:

Management of retroperitoneal sarcomas relies heavily on expert consensus and clinical trial participation.
International collaboration is crucial for advancing the understanding and treatment of these complex tumors.
Further research is needed to establish evidence-based guidelines for adjuvant and systemic therapies.